Gene & Cell Therapy and Rare Diseases’ Research
We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.
The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.
Our services include (amongst others):
For BioPharma clients:
- Market and competitor insights on R&D, clinical development and commercial activities
- Extensive congress coverage, supporting brand owners with up-to-date intelligence
- Landscape analysis strengthened by expert interviews
- BD&L support
For Investors:
- Due diligence research
- New opportunity identification
- Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews
We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.
Want to better understand and succeed in this complex space? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
August 13, 2026
Insulinova Partners with Ospedale San Raffaele | Lucid Diligence Brief
August 13, 2026
Rare Diseases Strategic Roundup | July 08 – Aug 12, 2026
August 10, 2026
Oncology Strategic Roundup | July 02 – Aug 07, 2026
August 7, 2026
Vaccine Strategic Roundup I July 06 – Aug 07, 2026
August 5, 2026
Women’s Health Strategic Roundup | June 24 – August 4, 2026
August 4, 2026
Curium Lantheus Merger | Lucid Diligence Brief
August 4, 2026
Genprex Roche Diagnostics TROP2 Collaboration | Lucid Diligence Brief
August 4, 2026
Healthcare AI and Digital Health Strategic Roundup | July 3 – August 2, 2026
July 31, 2026
Roche Ivy Tech Laboratory Workforce Partnership | Lucid Diligence Brief
July 31, 2026
Respiratory Strategic Roundup | June 25 – July 30, 2026
July 30, 2026